Cantor Fitzgerald Reaffirms "Overweight" Rating for Neurocrine Biosciences (NASDAQ:NBIX) : vimarsana.com

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report issued on Wednesday, Benzinga reports. They presently have a $155.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 14.03% from the company’s previous close. Several other […]

Related Keywords

United States , Stifel Nicolaus , Ingrid Delaet , Neurocrine Biosciences , Wells Fargo Company , Vanguard Group Inc , Goldman Sachs Group , Geode Capital Management , Cantor Fitzgerald , Neurocrine Biosciences Inc , Neurocrine Biosciences Company Profile , Pricet Rowe Associates Inc , Blackrock Inc , Securities Exchange Commission , Deutsche Bank Aktiengesellschaft , Get Free Report , Bank Aktiengesellschaft , Exchange Commission , Director George , Street Corp , Capital Management , Neurocrine Biosciences Daily , Nasdaq Nbix , Nbix , Medical , 64125c10 , Reiterated Rating ,